Actelion Pharmaceuticals UK is the British arm of Swiss biotech firm Actelion. The drug manufacturer's product pipeline is based on its research of the endothelium, the single layer of cells between blood vessels and the blood that flows through them. Its first products are Tracleer for the treatment of pulmonary arterial hypertension, and Zavesca which is used to treat Type 1 Gaucher disease.

QUATRx Pharmaceuticals hopes to capitalize on the bright ideas of others. The biopharmaceutical company acquires compounds in the pre-clinical stage from other companies and academic institutions and takes them through clinical studies then licensing them to pharma giants. The company focuses on developing new therapies for cardiovascular, endocrine, and metabolic conditions. Products in clinical trials include treatments for age-related hormone deficiencies in women and men as well as drugs for high cholesterol and the treatment of psoriasis. Hormos Medical, QUATRx's Finnish subsidiary, conducts most of its preclinical and discovery programs.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

Roche Holding Ltd. company operates two segments, pharmaceuticals and diagnostics, and sells its products in more than 150 countries. Roche's prescription drugs include cancer therapies MabThera/Rituxan and Herceptin, anemia treatment NeoRecormon/Epogin, hepatitis drug Pegasys, transplant drug CellCept, obesity treatment Xenical, and Tamiflu, which is used to prevent and treat influenza, including avian strains. The company markets many of its bestsellers through subsidiary Genentech and affiliate Chugai Pharmaceutical. Roche's diagnostics arm offers advanced DNA tests, diabetes monitoring supplies, and point-of-care diagnostics used in a variety of health care settings.

Goldshield Group plc, through its subsidiaries, engages in the development, marketing, and distribution of pharmaceutical and consumer health products. It offers ethical pharmaceuticals, non-prescription medicines, vitamins, minerals and supplements, and various other healthcare products. The company’s pharmaceutical products comprise Ostex, a glucosamine sulphate for joints; Flexeze for glucosamine; and Flexeze Truefil capsules for joints and connective tissues. Its pharmaceutical products are used for chronic disease areas, including cardiovascular diseases, central nervous system disorders, and musculoskeletal conditions. The company’s consumer health products include Appesat for natural weight loss; LIPObind, a natural weight management supplement; Lubramine, a supplement for joint health; Kamillosan, a breastfeeding product; and Infaderm, a soap-free bubble bath product. Its consumer health products also include joints and mobility, bone health, antioxidants, heart and circulation, digestion and detox, weight management, men’s health, women's health, skin care and beauty, heart and bone health, fitness nutrition, immune boosters, joint health, cardiac health, multi vitamins, pet health, centural specials, anti aging, eye health, and well being products. In addition, the company develops wellbeing villages and resorts; publishes magazines for consumers, as well as sells subscriptions and advertising space; and provides telemarketing and management services. Goldshield Group operates in the United Kingdom, Ireland, North America, and India. The company was founded in 1991 and is headquartered in Croydon, the United Kingdom. As of December 21, 2009, Goldshield Group plc was taken private.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Our lead product candidate is Silenor® (doxepin) for the treatment of insomnia. Silenor is a sleep-specific, low-dose (3mg and 6mg), oral tablet formulation of doxepin that is patent-protected for use in insomnia. In contrast to higher-dose doxepin, Silenor is a potent antagonist that appears to selectively block histamine at the H1 receptor without a clinically relevant impact on other neurotransmitter systems. Doxepin at higher doses has been associated with a range of pharmacologic side effects that include anticholenerigic effects (dry mouth, constipation, etc.) and weight gain. In clinical trials, patients taking Silenor generally did not exhibit the side effects associated with higher doses of doxepin.

Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Kailua-Kona, Hawaii. Mera Pharmaceuticals, Inc. primarily develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology known as the Mera Growth Module. Mera Pharmaceuticals company's product line consists of ASTAFACTOR, a nutraceutical and source of natural astaxanthin; and SALMON ESSENTIALS, a combination of astaxanthin and omega-3 fatty acids. It markets its products to retail outlets in Hawaii through distribution arrangements with established companies.

Lescarden Inc. was founded in 1960 and is based in New York, New York. Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. It also provides a line of Catrix-based skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, the company offers nutritional supplements, including BIO-CARTILAGE; and POLY-Nag, a glucosamine polymer for the treatment of osteoarthritis. It also licenses its technologies for commercialization by other companies in Canada, Europe, and Korea. The company sells its products primarily in Europe, the Philippines, and Korea.

Established in 2004, Merrion operates offices in North Carolina and Ireland. Merrion Pharmaceuticals wants to make complicated drug dosing regimens easier to swallow. A specialty pharmaceutical firm, Merrion develops (independently and in collaboration with other drug companies) oral drugs to replace already-approved injectable-only medicines. Using its patented drug delivery technologies, Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) improves the absorption of drugs into the blood stream. Its Gastrointestinal Retention System (GIRES) helps the stomach retain drugs, allowing for their extended, controlled release. The company has four candidates in the development pipeline.

Sanofi-Aventis was founded in 1970 and is headquartered in Paris, France. Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company's business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. In its pharmaceutical activity, Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. On September 1, 2008, Sanofi-Aventis acquired the Australian company, Symbion CP Holdings Pty Ltd (Symbion Consumer). On September 25, 2008, it acquired Acambis plc. In January 2009, the Company sold its French plant of Colomiers to French pharmaceutical company Unither. In April 2009, the Company acquired Mexican generic company, Laboratorios Kendrick.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.